Pharmaceuticals, Biotechnology & Life Sciences

Discover how Eli Lilly’s FDA approval of Mounjaro (tirzepatide) for cardiovascular risk in type 2 diabetes gives it a unique edge over GLP‑1 rivals and boosts investor prospects.

BCG

Explore CollPlant Biotechnologies, a Nasdaq‑listed biotech pushing 3D bioprinting for tissue repair and orthobiologics amid market volatility and future‑focused innovation.

BioCryst’s Japan approval for pediatric hereditary angioedema marks a milestone, expanding rare‑disease care and positioning the biotech firm for future global filings.

Explore how Novo Nordisk’s looming patent cliffs, new weight‑loss and hair‑loss opportunities, and defensive market status shape its future strategy.

Tenax Therapeutics to reveal Phase‑3 LEVEL study results for TNX‑103 at ESC 2026, showing a 55‑meter 6MWD gain and solid safety in PH‑HFpEF.

Legend Biotech’s fall from a $37.50 high to $19.88, a negative P/E of -41.05, raises red flags on its cell‑therapy promise and investor confidence.

Boundless Bio’s volatile $2.86 stock reflects biotech’s high‑risk, high‑reward reality—market cap, price swings, and investor insights in one snapshot.

BioXcel files for Chapter 11 and sells its BXCL501 drug to Teva for $57.5 million, a key move to liquidate assets and provide liquidity to creditors.

CollPlant Biotechnologies, Nasdaq‑listed and focused on 3D bioprinting, pioneers regenerative medicine for orthobiologics and advanced wound care, promising transformative healthcare solutions.